OMEGA THERAPEUTICS
Dead / Abandoned — Abandoned — failure to respond (as of 29 Nov 2023)
What this means for you
This application is over — abandoned 20 Nov 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97342595
- Mark type
- Stylized text
- Filed
- 01 Apr 2022
- Published for opposition
- 21 Feb 2023
- Abandoned
- 20 Nov 2023
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical agents affecting DNA structure by targeting DNA structure to treat various diseases in the nature of monogenic diseases, cancer, infectious disease, immune disease, hematological conditions, haploinsufficiencies, hepatic disease, channelopathies, endocrine disease, cardiovascular disease, reproductive disease, renal disease, skeletal muscle disease, bone disease, none of the foregoing including omega fatty acids
Owner
- Omega Therapeutics, Inc., Cambridge, MA, US
- Omega Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 29 Nov 2023 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 29 Nov 2023 — ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
- 29 Nov 2023 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 16 Aug 2023 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 16 Aug 2023 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 01 Jun 2023 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 01 Jun 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 01 Jun 2023 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 17 May 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 17 May 2023 — NON-FINAL ACTION E-MAILED
- 17 May 2023 — SU - NON-FINAL ACTION - WRITTEN
- 17 May 2023 — STATEMENT OF USE PROCESSING COMPLETE
- 26 Apr 2023 — USE AMENDMENT FILED
- 16 May 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 26 Apr 2023 — TEAS STATEMENT OF USE RECEIVED